Yahoo
NasdaqCM - Delayed Quote USD

Atossa Therapeutics, Inc. (ATOS)

2.5200 -0.0100 (-0.40%)
At close: September 4 at 4:00:01 PM EDT
2.5200 0.0000 (0.00%)
After hours: September 4 at 7:30:01 PM EDT
Chart Range Bar
Loading chart for ATOS
  • Previous Close 2.5300
  • Open 2.5100
  • Bid 1.7800 x 200
  • Ask 3.3000 x 200
  • Day's Range 2.5000 - 2.6000
  • 52 Week Range 1.7000 - 19.3500
  • Volume 28,019
  • Avg. Volume 156,974
  • Market Cap (intraday) 25.148M
  • Beta (5Y Monthly) 1.27
  • PE Ratio (TTM) --
  • EPS (TTM) -4.3100
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 18.67

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

www.atossatherapeutics.com

16

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ATOS
71.53%
S&P 500 (^GSPC)
12.75%

1-Year Return

ATOS
78.18%
S&P 500 (^GSPC)
18.71%

3-Year Return

ATOS
79.00%
S&P 500 (^GSPC)
70.93%

5-Year Return

ATOS
95.52%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -8.49M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-10M
-8M
-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

10.00
18.67 Average
2.5200 Current
24.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/7/2026
Analyst Rodman & Renshaw
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 12

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    24.15M

  • Enterprise Value

    -1.94M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.90

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -50.69%

  • Return on Equity (ttm)

    -89.23%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -37.71M

  • Diluted EPS (ttm)

    -4.3100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    26.09M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -23.33M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.5200 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: